Orcrist Bio Inc. Receives Approval from European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750

    CALGARY, April 6 /CNW/ - Orcrist Bio Inc. (ORC) a biotechnology company
developing stem cell-mobilizing pharmaceuticals, announced today the approval
of its Phase I, open-label, single-ascending-dose, safety study of HYC750 in
healthy male volunteers, by the European Competent Authority in Seville,
Spain. The goal of the study is to assess the safety, tolerability,
pharmacokinetics and pharmacodynamics (induction of hematopoiesis) of HYC750,
a patent-protected formulation of hyaluronan. The planned study will be
conducted by InPEC BV (Breda, Netherlands) at their clinical trial site in
Malaga, Spain.
    "The approval of our Phase I clinical trial by the European authorities
is another significant accomplishment for Orcrist," said Dr. Brett Schonekess,
President and CEO of Orcrist. "With this approval we are now positioned to
move forward with InPEC as our clinical partner and further develop HYC750
with the goal of confirming its safety profile, and to provide for a clear
illustration of its stem cell mobilization properties. Ultimately, this is a
key step to further advance the development of our product as a treatment for
chemotherapy-related blood cell depletion."

    About Orcrist Bio Inc.

    Orcrist Bio Inc. is a biotechnology company dedicated to developing and
commercializing promising therapeutics for areas in which a clear market
opportunity exists. ORC's lead program revolves around HYC750, a novel stem
cell mobilizer compound that promotes the egress of stem cells and other blood
cells from the bone marrow into the blood, from which they can be harvested
and applied toward treating chemotherapy-related blood cell depletion. Orcrist
is actively looking to add to its pipeline exploring the innate properties of
HYC750 and its effects on stem cells, as well as through in-licensing
opportunities of other products with clear market potential. ORC is located in
Calgary, Alberta. The company is financed by its founders and by private

    About InPEC BV

    InPEC BV is a clinical CRO that focuses on the execution of Phase I and
IIa clinical trials. Its professional and experienced team, and state of the
art facilities, embedded within the care of a private hospital with an ICU
unit on the same floor, guarantee maximum safety for the full range of
clinical pharmacology studies. Electronic data processing procedures are in
place to enable high-quality and efficient data processing on-site. InPEC's
head office is located in the Netherlands. Clinical facilities are located in
Malaga, Spain.

For further information:

For further information: on Orcrist Bio Inc., please see our website
www.orcristbio.com; Contact information: Dr. Brett Schonekess, President and
CEO, Phone: (403) 984-3882 x 222, Email: brett@orcristbio.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890